Conclusions
SECONDARY
In this analysis of secondary end points for a randomized noninferiority trial, we found that 6-month PrEP dispensing supported with interim HIVST reduced the number of clinic visits in half with generally noninferior PrEP continuation outcomes at 12 months compared with standard quarterly PrEP dispensing. PrEP provides high efficacy and safety for HIV prevention; continuing to optimize its delivery for those who could benefit is essential to ending the global HIV epidemic.